Insights on T-DXd and Emerging Research on ADCs in HR+/HER2-Low Breast Cancer
June 27th 2024Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, share advice for community oncologists on the utilization of T-DXd and discuss the future outlook for antibody-drug conjugates in HR+/HER2-low breast cancer.
Best Candidates for HER2-Directed ADCs in HR+/HER2-Low Metastatic Breast Cancer
June 27th 2024Experts on breast cancer describe the best candidates for HER2-directed antibody-drug conjugates in HR+/HER2-low metastatic breast cancer, highlighting the role of trastuzumab deruxtecan in later lines of therapy.